Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02165293 · ClinicalTrials.gov registry record · Phase 1
A Single Center Study to Evaluate the Penetration of RO7033877 Into the Lung in Healthy Volunteers
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02165293 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 32 participants.
The verdict
NCT02165293, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This single-center, open-label study will investigate RO7033877 concentrations in plasma and in various lung compartments, including epithelial lining fluid (ELF), and alveolar macrophages (AM) in healthy volunteers after multiple intravenous (IV) administration. Bronchoscopy will be performed after the start of the last infusion on Day 3 at different timepoints. Blood, urine and brochoalveolar lavage samples will be collected to determine RO7033877 concentrations. The anticipated time on study treatment is 3 days.
Interventions
- DRUG RO7033877 + Bronchoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02165293
The ClinicalTrials.gov registry entry for NCT02165293 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO7033877 + Bronchoscopy is the first listed.
NCT02165293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02165293 about?
NCT02165293 is a clinical study titled "A Single Center Study to Evaluate the Penetration of RO7033877 Into the Lung in Healthy Volunteers". This single-center, open-label study will investigate RO7033877 concentrations in plasma and in various lung compartments, including epithelial lining fluid (ELF), and alveolar macrophages (AM) in healthy volunteers after multiple intravenous (IV) administration. Bronchoscopy will be performed after...
What is the current status of trial NCT02165293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-06. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02165293?
The interventions under investigation include: RO7033877 + Bronchoscopy (DRUG).
Who is sponsoring clinical trial NCT02165293?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.